Inspiremd Stock Price, News & Analysis

InspireMD reported a 47.8% growth in CGuard™ revenue year-over-year, achieving $1,505,000 in the second quarter of 2022. This surge in sales volume came from selling 2,602 stent systems compared to 1,623 in Q2 2021. Despite the positive revenue growth, the company's net loss widened to $4,636,000 or $0.59 per share, up from $3,507,000, as operating expenses increased significantly. Total revenue for the first half of 2022 reached $2,714,000, marking a 32.8% rise year-over-year.

InspireMD (Nasdaq: NSPR) will report its second quarter 2022 financial results on August 9, 2022, before market opening. The company, known for the CGuard™ Embolic Prevention Stent System, aims to provide significant clinical advancements in treating carotid artery disease. A conference call will occur at 8:30 a.m. EDT on the same day to discuss these results and corporate updates. InspireMD focuses on ensuring long-term stroke-free outcomes through its proprietary MicroNet® technology.

InspireMD, Inc. (Nasdaq: NSPR) appointed endovascular pioneer Dr. Juan Parodi as a strategic advisor on July 14, 2022. Known for performing the first endovascular repair procedure in 1990, Dr. Parodi brings significant expertise to InspireMD's efforts in stroke prevention. CEO Marvin Slosman emphasized Dr. Parodi's contributions to vascular surgery, particularly with the CGuard™ Embolic Prevention System, which aims to enhance patient outcomes in carotid artery disease. Dr. Parodi's involvement underscores InspireMD's commitment to innovation and clinical performance.

InspireMD (Nasdaq: NSPR) showcased its CGuard™ Embolic Prevention System at the LINC 2022 conference, emphasizing its advantages in carotid revascularization. A successful live procedure highlighted CGuard's optimal vessel conformability and MicroNet mesh technology, offering superior patient protection. Results from various studies presented at LINC demonstrated significantly lower rates of death, stroke, and myocardial infarction with CGuard compared to traditional stents, reinforcing its market leadership in stroke prevention.

InspireMD will showcase its CGuard™ Embolic Prevention System (EPS) at the upcoming LINC 2022 conference in Leipzig, Germany, from June 6-9. The live case transmission aims to exhibit the system's ease-of-use and patient safety features. CEO Marvin Slosman highlighted the significance of the event for engaging with the clinical community. Presentations will feature evidence supporting the superiority of CGuard™ EPS over conventional stents. The conference serves as a vital platform for discussing advancements in vascular medicine.

InspireMD reported a 20% increase in CGuard™ revenue, totaling $1,161,000 for Q1 2022. The company completed its first European enrollment in the C-Guardian FDA trial and established a logistics hub with BOMI Group to enhance market access. Despite operating expenses rising by 34.7% to $4,608,000, total revenue grew by 17.6%. However, the net loss increased to $4,481,000, or $0.57 per share. The CEO emphasized ongoing efforts in expanding market share and improving clinical outcomes.

InspireMD (Nasdaq: NSPR) will announce its first quarter 2022 financial results on May 10, 2022, before market opening. A conference call is scheduled for 8:30 a.m. ET the same day to review these results and discuss corporate developments. The call will be accessible via a webcast. InspireMD aims to utilize its MicroNet® technology for improving the outcomes in carotid stenting.

InspireMD, Inc. (Nasdaq: NSPR) has announced a Key Opinion Leader (KOL) webinar on its CGuard™ Embolic Prevention Stent System for treating Carotid Artery Disease and stroke prevention.

The webinar is scheduled for March 22, 2022, at 2 p.m. ET, featuring experts including Chris Metzger, Adnan Siddiqui, and Sean Lyden. They will discuss the unmet needs in the carotid/neurovascular market and how InspireMD's products could fill this gap.

The management team will share insights about leveraging their MicroNet technology to enhance stroke prevention and patient outcomes.

InspireMD reported strong revenue growth driven by its CGuard™ EPS, achieving an 87.5% increase in Q4 2021 over Q4 2020, totaling $1,291,000, and a 55.9% year-over-year growth for the full year with $4,495,000. The company established reimbursement approval for CGuard from the French National Authority and its inclusion in a major clinical trial. However, it reported a net loss of $4,097,000 for Q4 2021, widening from the previous year's loss. Despite expenses rising 27% due to clinical trials and expansion efforts, cash reserves stood strong at $34.0 million.